Eli Lilly launched a service to sell its weight-loss drugs directly to the public. That pits the company against startups such as Ro and Noom that have fed the frenzy over GLP-1 medications by making them easy to access online.
The drugmaker’s new digital healthcare platform, dubbed LillyDirect, will help connect patients with obesity, diabetes and migraines to doctors who can prescribe medications including Mounjaro and Zepbound, the company said in a statement Thursday. It will also offer direct home delivery of certain drugs through third-party pharmacies, Lilly has partnered with closely-held Form Health, a virtual weight loss program, on obesity and will work with 9amHealth on its diabetes offerings.
